Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 1 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  2. US 12404508

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  3. US 12397013

    Extrahepatic delivery

    Alnylam Pharmaceuticals, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  4. US 12385043

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  5. US 12385044

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  6. US 12378553

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  7. US 12364762

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  8. US 12350338

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  9. US 12343398

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  10. US 12338439

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  11. US 12331297

    Coagulation factor V (F5) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  12. US 12290573

    Modified RNAi agents

    Alnylam Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  13. US 12241064

    REVERSIR™ compounds

    Alnylam Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  14. US 12239709

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  15. US 12227744

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  16. US 12221607

    Multi-targeted single entity conjugates

    Alnylam Pharmaceuticals, Inc. · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  17. US 12173288

    Oligonucleotide-ligand conjugates and process for their preparation

    Alnylam Pharmaceuticals, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  18. US 12173289

    Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  19. US 12168767

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  20. US 12091666

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  21. US 12071619

    SERPINA1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  22. US 12059468

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  23. US 12049628

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  24. US 12049630

    Factor XII (F12) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted